N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors

A compound of Formula I-2:

• or a stereoisomer, tautomer, or pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
• Ring A is formula A-1
• m is 1 or 2;
• R1 is formula R1-1, R1-2 or R1-3
• Y1 is CH3CH2—, CF3CH2—, CH3O—, F3CO—, F2CHO—, FCH2O—, CH3S—, F3CS—, F2CHS—, or FCH2S—;
• Y2 is O, S, NH, MeN— or CH2;
• Y3 is CH3O—, CH3S—, MeNH— or Me2N—;
• Y4 is CH2 and Y5 is S or O, or Y4 is S or O and Y5 is CH2;
• R2 is halogen or (1-3C)alkyl (optionally substituted with 1-3 fluoros);
• X is O, S, NH or N—CN;
• Ring C is formula C-1
• R3 is Ar2;
• Ar2 is phenyl;
• R4 is (1-6C)alkoxy, dihydroxy(2-6C)alkoxy, hetCyc2(1-6C)alkoxy, hetAr4, aminocarbonyl, hetCyc3, or hetAr5;
• hetCyc2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with (1-6C)alkyl, (1-4C alkylcarboxy)(1-6C)alkyl, or halogen;
• hetCyc3 is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with CN or (1-6C)alky;
• hetAr4 is a 5-6 membered heteroaryl ring having 1-3 ring nitrogen heteroatoms and optionally substituted with (1-6C)alkyl;
• hetAr5 is
• where Rz is (1-3C)alkyl (optionally substituted with 1-3 fluoros);
• and
• R5 is (1-6C)alkyl.